The liquid biopsy era is finally here.
Natera’s cancer blood test is couture, but Guardant’s pret-a-porter offering might sell better.
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.
Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Blood tests could be faster and cheaper than tissue biopsies, but a Thermo Fisher exec argues they are likely to be more of an add-on technique.
Two closely-watched liquid biopsy developers are to present data on their respective solid tumour blood tests.
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.